R-Tech Ueno Announces Settlement Deal That Resolves Patent Litigation In U.S.

(RTTNews) - Sucampo Pharmaceuticals, Inc. (SCMP) announced that it, its affiliate Sucampo AG, R-Tech Ueno, Ltd., Takeda Pharmaceutical Company Ltd. (TKPYY.PK, TKPHF.PK), and certain affiliates of Takeda have signed a settlement and license deal with Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. (PRX) that resolves patent litigation in the U.S. related to Sucampo's AMITIZA 8 mcg soft gelatin capsule and 24 mcg soft gelatin capsule. Further details of the deal remain confidential.

As part of the settlement, Sucampo and RTU would grant Par a non-exclusive license to market Par's generic version of lubiprostone 8 mcg soft gelatin capsule and 24 mcg soft gelatin capsule in the U.S. for the indications approved for AMITIZA beginning January 1, 2021, or earlier under certain circumstances. Beginning on January 1, 2021, Par would split with Sucampo the gross profits of the licensed products sold during the agreement term, which continues until each of the Sucampo patents has expired. In the event Par elects to launch an authorized generic, Sucampo would supply Par under the terms of a manufacturing and supply agreement at a negotiated price.

In addition, Sucampo, RTU, Takeda, and Par have agreed to dismiss with prejudice the patent litigation filed in the U.S. District Court for the District of Delaware.